Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 669-678

  Stricker, Thomas P ^a   Morales La Madrid, Andres ^b,l   Chlenski, Alexandre ^b   Guerrero, Lisa ^b   Salwen, Helen R ^b   Gosiengfiao, Yasmin ^c   Perlman, Elizabeth J ^c   Furman, Wayne ^d   Bahrami, Armita ^d   Shohet, Jason M ^e   Zage, Peter E ^e   Hicks, M John ^e   Shimada, Hiroyuki ^f   Suganuma, Rie ^f   Park, Julie R ^g,h   So, Sara ^g,h   London, Wendy B ^i,j   Pytel, Peter ^b   Maclean, Kirsteen H ^k   Cohn, Susan L ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ Children's Oncology Group Statistics and Data Center   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k NANOSTRING TECHNOLOGIES   (United States)

^l HOSPITAL SANT JOAN DE DÉU   (Spain)

more..

Author keywords

Gene signature; High risk neuroblastoma; Molecular classifier; NanoString; NCounter

Indexed keywords

FORMALDEHYDE; OLIGONUCLEOTIDE; PARAFFIN; TUMOR MARKER;

ANALYZER; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; CORRELATIONAL STUDY; EVENT FREE SURVIVAL; GENE EXPRESSION; HIGH RISK PATIENT; HIGH THROUGHPUT SCREENING; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; CLUSTER ANALYSIS; DEVICES; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; INFANT; PROGNOSIS; VALIDATION STUDY;

CLUSTER ANALYSIS; COHORT STUDIES; GENE EXPRESSION PROFILING; HUMANS; INFANT; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 84899490698     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.01.010     Document Type: Article

References (31)

1. Abel F., Dalevi D., Nethander M., Jornsten R., De Preter K., Vermeulen J., Stallings R., Kogner P., Maris J., Nilsson S. A 6-gene signature identifies four molecular subgroups of neuroblastoma. Cancer Cell Int. 2011, 11:9.
2. Asgharzadeh S., Pique-Regi R., Sposto R., Wang H., Yang Y., Shimada H., Matthay K., Buckley J., Ortega A., Seeger R.C. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J.Natl. Cancer Inst. 2006, 98:1193-1203.
3. Ben-Yosef T., Yanuka O., Halle D., Benvenisty N. Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene 1998, 17:165-171.
4. Brodeur G.M., Pritchard J., Berthold F., Carlsen N.L., Castle V., Castelberry R.P., De Bernardi B., Evans A.E., Favrot M., Hedborg F., Kaneko M., Kemshead J., Lampert F., Lee R.E.J., Look A.T., Pearson A.D.J., Philip T., Roald B., Sawada T., Seeger R.C., Tsuchida Y., Voute P.A. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J.Clin. Oncol. 1993, 11:1466-1477.
5. Cohn S.L., Pearson A.D., London W.B., Monclair T., Ambros P.F., Brodeur G.M., Faldum A., Hero B., Iehara T., Machin D., Mosseri V., Simon T., Garaventa A., Castel V., Matthay K.K., Force I.T. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J.Clin. Oncol. 2009, 27:289-297.
6. De Preter K., Vermeulen J., Brors B., Delattre O., Eggert A., Fischer M., Janoueix-Lerosey I., Lavarino C., Maris J.M., Mora J., Nakagawara A., Oberthuer A., Ohira M., Schleiermacher G., Schramm A., Schulte J.H., Wang Q., Westermann F., Speleman F., Vandesompele J. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin. Cancer Res. 2010, 16:1532-1541.
7. Fernandez P., Solenthaler M., Spertini O., Quarroz S., Rovo A., Lovey P.Y., Leoncini L., Ruault-Jungblut S., D'Asaro M., Schaad O., Docquier M., Descombes P., Matthes T., Swiss Cytometry S. Using digital RNA counting and flow cytometry to compare mRNA with protein expression in acute leukemias. PLoS One 2012, 7:e49010.
8. Furman W.L., McGregor L.M., McCarville M.B., Onciu M., Davidoff A.M., Kovach S., Hawkins D., McPherson V., Houghton P.J., Billups C.A., Wu J., Stewart C.F., Santana V.M. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest. New Drugs 2012, 30:1660-1670.
9. Garcia I., Mayol G., Rios J., Domenech G., Cheung N.K., Oberthuer A., Fischer M., Maris J.M., Brodeur G.M., Hero B., Rodriguez E., Sunol M., Galvan P., de Torres C., Mora J., Lavarino C. A three-gene expression signature model for risk stratification of patients with neuroblastoma. Clin. Cancer Res. 2012, 18:2012-2023.
10. Geiss G.K., Bumgarner R.E., Birditt B., Dahl T., Dowidar N., Dunaway D.L., Fell H.P., Ferree S., George R.D., Grogan T., James J.J., Maysuria M., Mitton J.D., Oliveri P., Osborn J.L., Peng T., Ratcliffe A.L., Webster P.J., Davidson E.H., Hood L., Dimitrov K. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 2008, 26:317-325.
11. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J.Am. Stat. Assoc. 1958, 53:457-481.
12. Kletzel M., Katzenstein H.M., Haut P.R., Yu A.L., Morgan E., Reynolds M., Geissler G., Marymount M.H., Liu D., Kalapurakal J.A., Shore R.M., Bardo D.M., Schmoldt J., Rademaker A.W., Cohn S.L. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II study. J.Clin. Oncol. 2002, 20:2284-2292.
13. Kreissman S.G., Seeger R.C., Matthay K.K., London W.B., Sposto R., Grupp S.A., Haas-Kogan D.A., Laquaglia M.P., Yu A.L., Diller L., Buxton A., Park J.R., Cohn S.L., Maris J.M., Reynolds C.P., Villablanca J.G. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013, 14:999-1008.
14. Kulkarni M.M. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr. Protoc. Mol. Biol. 2011, 94. 25B.10.1-25B.10.17.
15. Malkov V.A., Serikawa K.A., Balantac N., Watters J., Geiss G., Mashadi-Hossein A., Fare T. Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter assay system. BMC. Res. Notes 2009, 2:80.
16. Maris J.M. Recent advances in neuroblastoma. N.Engl. J. Med. 2010, 362:2202-2211.
17. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
18. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., Gerbing R.B., London W.B., Villablanca J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J.Clin. Oncol. 2009, 27:1007-1013.
19. Northcott P.A., Shih D.J., Remke M., Cho Y.J., Kool M., Hawkins C., Eberhart C.G., Dubuc A., Guettouche T., Cardentey Y., Bouffet E., Pomeroy S.L., Marra M., Malkin D., Rutka J.T., Korshunov A., Pfister S., Taylor M.D. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012, 123:615-626.
20. Oberthuer A., Hero B., Berthold F., Juraeva D., Faldum A., Kahlert Y., Asgharzadeh S., Seeger R., Scaruffi P., Tonini G.P., Janoueix-Lerosey I., Delattre O., Schleiermacher G., Vandesompele J., Vermeulen J., Speleman F., Noguera R., Piqueras M., Benard J., Valent A., Avigad S., Yaniv I., Weber A., Christiansen H., Grundy R.G., Schardt K., Schwab M., Eils R., Warnat P., Kaderali L., Simon T., Decarolis B., Theissen J., Westermann F., Brors B., Fischer M. Prognostic impact of gene expression-based classification for neuroblastoma. J.Clin. Oncol. 2010, 28:3506-3515.
21. Payton J.E., Grieselhuber N.R., Chang L.W., Murakami M., Geiss G.K., Link D.C., Nagarajan R., Watson M.A., Ley T.J. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J.Clin. Invest. 2009, 119:1714-1726.
22. Santana V.M., Furman W.L., Billups C.A., Hoffer F., Davidoff A.M., Houghton P.J., Stewart C.F. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J.Clin. Oncol. 2005, 23:4039-4047.
23. Schramm A., Schulte J.H., Klein-Hitpass L., Havers W., Sieverts H., Berwanger B., Christiansen H., Warnat P., Brors B., Eils J., Eils R., Eggert A. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005, 24:7902-7912.
24. Schulte J.H., Schowe B., Mestdagh P., Kaderali L., Kalaghatgi P., Schlierf S., Vermeulen J., Brockmeyer B., Pajtler K., Thor T., de Preter K., Speleman F., Morik K., Eggert A., Vandesompele J., Schramm A. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int. J. Cancer 2010, 127:2374-2385.
25. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., Stram D.O., Gerbing R.B., Lukens J.N., Matthay K.K., Castleberry R.P. The international neuroblastoma pathology classification (the Shimada system). Cancer 1999, 86:364-372.
26. Storey J.D. A direct approach to false discovery rates. J.Roy Stat. Soc. Ser. B 2002, 64:479-498.
27. Stricker T.P., Henriksen K.J., Tonsgard J.H., Montag A.G., Krausz T.N., Pytel P. Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation. Mod. Pathol. 2013, 26:930-943.
28. Vermeulen J., De Preter K., Naranjo A., Vercruysse L., Van Roy N., Hellemans J., Swerts K., Bravo S., Scaruffi P., Tonini G.P., De Bernardi B., Noguera R., Piqueras M., Canete A., Castel V., Janoueix-Lerosey I., Delattre O., Schleiermacher G., Michon J., Combaret V., Fischer M., Oberthuer A., Ambros P.F., Beiske K., Benard J., Marques B., Rubie H., Kohler J., Potschger U., Ladenstein R., Hogarty M.D., McGrady P., London W.B., Laureys G., Speleman F., Vandesompele J. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009, 10:663-671.
29. Wagner L.M., Billups C.A., Furman W.L., Rao B.N., Santana V.M. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J.Clin. Oncol. 2004, 22:1886-1893.
30. Wang Q., Diskin S., Rappaport E., Attiyeh E., Mosse Y., Shue D., Seiser E., Jagannathan J., Shusterman S., Bansal M., Khazi D., Winter C., Okawa E., Grant G., Cnaan A., Zhao H., Cheung N.K., Gerald W., London W., Matthay K.K., Brodeur G.M., Maris J.M. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006, 66:6050-6062.
31. Wei J.S., Greer B.T., Westermann F., Steinberg S.M., Son C.G., Chen Q.R., Whiteford C.C., Bilke S., Krasnoselsky A.L., Cenacchi N., Catchpoole D., Berthold F., Schwab M., Khan J. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004, 64:6883-6891.